Ken Fisher
RARE icon

Ken Fisher’s Ultragenyx Pharmaceutical RARE Stock Holding History

Ken Fisher’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-198,696
Closed -$4.57M – 1094
2025
Q4 		$4.57M Buy
198,696
+30,612
+18% +$1.01M ﹤0.01% 476
2025
Q3 		$5.06M Sell
168,084
-17,672
-10% -$530K ﹤0.01% 479
2025
Q2 		$6.75M Sell
185,756
-21,999
-11% -$793K ﹤0.01% 444
2025
Q1 		$7.52M Sell
207,755
-57,434
-22% -$2.39M ﹤0.01% 449
2024
Q4 		$11.2M Buy
+265,189
New +$13.2M ﹤0.01% 418

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Ken Fisher's RARE Position: Q1 2026 in Review

Ken Fisher sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2026, closing a stake of 198,696 shares — an estimated $4.57M sold.

Ken Fisher first reported a position in RARE in Q4 2024 and held it in 5 quarters. The position peaked at $11.2M in Q4 2024. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Ken Fisher reported no remaining Ultragenyx Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • Ken Fisher sold 198,696 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $4.57M.
  • Ken Fisher first reported a position in Ultragenyx Pharmaceutical in Q4 2024 and held it in 5 quarters.
  • Ken Fisher's Ultragenyx Pharmaceutical position peaked at $11.2M in Q4 2024.
  • 296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Fisher Asset Management's 13F filing for Q1 2026, filed 5 May 2026.